An antinuclear antibody result of nucleolar and nuclear homogeneous means that the fluorescence karyotype of this antinuclear antibody is nucleolar and nuclear homogeneous, which may be related to some autoantibodies. The target antigens of antinuclear antibodies include the nucleus and cytoplasm of the cell. Since the detection of antinuclear antibodies requires the application of fluorescence, the fluorescence intensity and fluorescence karyotype of the antinuclear antibodies can be observed under the microscope, and the clinic often categorizes them according to their karyotypes, and there are currently five main types, i.e., homogeneous karyotypes, speckled karyotype, nuclear membrane karyotype, nucleolus karyotypes, and nucleolus tidemarks karyotypes; nucleolus karyotype and nucleolus homogeneous karyotypes are exactly two of them. The antibodies associated with the nucleolar type are low molecular weight ribonucleic acid (RNA) specific to the nucleolus, etc. The high titer is specific for the diagnosis of scleroderma, but can also be seen in Raynaud’s phenomenon and occasionally in systemic lupus erythematosus. The nuclear homogeneous form is most often caused by anti-deoxyribonucleoprotein antibodies, but can also be caused by antibodies to nucleosomes and anti-double-stranded DNA antibodies; high titers are seen mainly in SLE, while low titers can be seen in patients with rheumatoid arthritis, chronic liver disease, infectious mononucleosis, or drug-induced lupus. When abnormalities of antinuclear antibodies occur, it is recommended to consult a doctor in a timely manner, to clarify the cause of the disease under the guidance of the doctor, and to follow the doctor’s instructions to actively standardize the treatment.